Rational Pharmacotherapy in Cardiology

Advanced search

Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation

Full Text:


Atrial fibrillation (AF) is one of the most common cardiac arrhythmias in clinical practice and important additional risk factor for the development of cognitive impairment (CI) and dementia as it has been shown in recent studies. According to the Diagnostic and statistical manual of mental disorders latest revision CI refers to a decrease of one or more higher cortical functions that provide the processes of perception, storage, transformation and transmission of information compared to the premorbid level. The main hypothesis that explains the relationship between AF and dementia is the assumption that in the presence of this arrhythmia a brain substance is damaged due to microembolism and cerebral microbleeding. The high clinical significance of AF as well as CI served as a background for the development by European experts several consensus documents concerning the problem of the relationships between these conditions. In addition, they emphasize the role of anticoagulant therapy as a preventing tool for the development of stroke, which can be a factor in the CI progression in patients with AF, with particular priority to direct oral anticoagulants (DOACs). In randomized clinical trials, meta-analyses and systematic reviews have been shown that the use of DOACs, as compared to vitamin K antagonists, is a more rational strategy for preventing stroke associated with AF. Among the DOAC class, rivaroxaban is worth noticing as a drug that has a favorable efficacy profile for primary and secondary stroke prevention. Rivaroxaban distinguishing characteristics are a once daily administration as well as a calendar package which is practically important for patients with CI.

About the Authors

O. D. Ostroumova
Pirogov Russian National Research Medical University, Russian Clinical and Research Center of Gerontology; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Head of Laboratory of Clinical Pharmacology and Pharmacotherapy, Russian Gerontology Clinical Research Center, Pervaya Leonova ul. 16, Moscow, 129226;

Professor, Chair of Clinical Pharmacology and Propaedeutics of Internal Medicine, Trubetskaya ul. 8-2, Moscow, 119991 

A. I. Kochetkov
Pirogov Russian National Research Medical University, Russian Clinical and Research Center of Gerontology
Russian Federation

MD, PhD, Researcher, Laboratory of Clinical Pharmacology and Pharmacotherapy, Russian Gerontology Clinical Research Center;

Assistant, Chair of Aging Diseases,

Pervaya Leonova ul. 16, Moscow, 129226 

S. P. Korchagina
Moscow City Clinical Hospital №52
Russian Federation

MD, Neurologist,

Pekhotnaya ul. 3, Moscow, 123182

T. M. Ostroumova
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

MD, PhD, Assitant, Chair of Nervous Diseases and Neurosurgery,

Trubetskaya ul. 8-2, Moscow, 119991 

M. S. Chernyaeva
War Veterans Hospital №2
Russian Federation

MD, PhD, General practitioner,

Volgogradsky prosp. 168, Moscow, 109472

A. A. Kirichenko
Russian Medical Academy of Continuing Professional Education
Russian Federation

MD, PhD, Professor, Head of Chair of therapy, 

Barrikadnaya ul. 2, Moscow, 123242 


1. Jankowska-Polańska B, Katarzyna L, Lidia A et al. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol. 2016;13(7):559-65. DOI:10.11909/j.issn.1671-5411.2016.07.006.

2. Chugh S.S., Havmoeller R., Narayanan K., et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129(8):837-47. DOI:10.1161/CIRCULATIONAHA.113.00511.

3. Orkaby A.R., Ozonoff A., Reisman J.I., et al. Continued Use of Warfarin in Veterans with Atrial Fibrillation After Dementia Diagnosis. J Am Geriatr Soc. 2017;65(2):249-56. DOI:10.1111/jgs.14573.

4. Bjorck S., Palaszewski B., Friberg L., Bergfeldt L. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. Stroke. 2013;44(11):3103-8. DOI:10.1161/STROKEAHA.113.002329.

5. Haim M., Hoshen M., Reges O., et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association. 2015;4(1):e001486. DOI:10.1161/JAHA.114.001486.

6. Diener H.C., Hart R.G., Koudstaal P.J., et al. Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week. J Am Coll Cardiol. 2019;73(5):612-9. DOI:10.1016/j.jacc.2018.10.077.

7. Ostroumova O.D., Cherniaeva M.S., Golovina O.V. Atrial fibrillation as Risk Factor for Development of Cognitive Function Impairment and Dementia. Potential of Anticoagulant Therapy in Their Prevention. Kardiologiia. 2018;58(9):76-88 (In Russ.). DOI:10.18087/cardio.2018.9.10173.

8. Kwok C.S., Loke Y.K., Hale R., et al. Atrial fibrillation and incidence of dementia: a systematic review and meta-analysis. Neurology. 2011;76(10):914-22. DOI:10.1212/WNL.0b013e31820f2e38.

9. Kalantarian S., Stern T.A., Mansour M., Ruskin J.N. Cognitive impairment associated with atrial fibrillation: a meta-analysis. Ann Intern Med. 2013;158:338-46. DOI:10.7326/0003-4819-158-5-201303050-00007.

10. Dagres N., Chao T.F., Fenelon G., et al.; ESC Scientific Document Group. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice? Europace. 2018;20(9):1399-421. DOI:10.1093/europace/euy046.

11. Purandare N. Prevention of dementia: Role of vascular risk factors and cerebral emboli. Indian J Psychiatry. 2009;51(1):S39-43.

12. Duron E., Hanon O. Vascular risk factors, cognitive decline, and dementia. Vasc Health Risk Manag. 2008;4(2):363-81. DOI:10.2147/VHRM.S1839.

13. Viswanathan A., Rocca W.A., Tzourio C. Vascular risk factors and dementia: how to move forward? Neurology. 2009;72(4):368-74. DOI:10.1212/01.wnl.0000341271.90478.8e.

14. Steffel J., Verhamme P., Potpara T.S., et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace. 2018;19:1-12. DOI:10.1093/europace/euy054.

15. Diagnostic and statistical manual of mental diseases (DSM-V). 5th ed. London: American Psychiatric Association; 2013.

16. Zakharov V.V. Cognitive Impairment no Dementia: Classification, Major Causes, and Treatment. Effektivnaya farmakoterapiya. Nevrologiya i Psihiatriya. 2016;(1):22-30 (In Russ.)

17. Jessen F., Amariglio R.E., van Boxtel M., et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimer’s and Dementia 2014;10(6):844- 52. DOI:10.1016/j.jalz.2014.01.001.

18. Yahno N.N., Zaharov V.V., Lokshina A.B., et al. Dementia: guidelines for doctors. Moscow: MED press-inform; 2011. (In Russ.) [Яхно Н.Н., Захаров В.В., Локшина А.Б., и др. Деменции: руководство для врачей. М.: МЕДпреcс-информ; 2011].

19. Damulin I.V. Cognitive disorder. Some issues of clinical picture, diagnosis, therapy. Moscow; 2012. (In Russ.) [Дамулин И.В. Когнитивные расстройства. Некоторые вопросы клиники, диагностики, лечения. М.; 2012].

20. Prince M., Bryce R., Albanese E., et al. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s and Dementia 2013;9(1):63-75. DOI:10.1016/j.jalz.2012.11.007.

21. Tham W., Auchus A.P., Thong M., et al. Progression of cognitive impairment after stroke: one-year results from a longitudinal study of Singaporean stroke patients. Journal of the Neurological Sciences. 2002;203-204:49-52. DOI:10.1016/s0022-510x(02)00260-5.

22. Pasquier F., Leys D. Why are stroke patientsprone to develop dementia? Journal of Neurology 1997;244(3):135-42. DOI:10.1007/s004150050064.

23. Levin O.S., Usoltseva N.I. Risk factors and dynamics of cognitive impairment in the early recovery period of ischemic stroke. Klinicheskaya Nevrologiya. 2007;2:3-5 (In Russ.).

24. Levin O.S., Usoltseva N.I., Dudarova M.A. Cognitive disorders in the early rehabilitative period of ischemic stroke. Russian Medical Journal. 2009;4:20-5 (In Russ.)

25. Zakharov V.V., Vakhnina N.V. Stroke and cognitive disorders. Neurology, Neuropsychiatry, Psychosomatics. 2011;(2):8-16. (In Russ.)

26. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-962. DOI:10.1093/eurheartj/ehw210.

27. Trubin V., Nikolaeva N., Paleeva M., Gavdifattova S. The elderly population of Russia: problems and prospects. Social Bulletin. 2016;(5):3-45 (In Russ.)

28. Silva R.M.F.L.D., Miranda C.M., Liu T., et al. Atrial Fibrillation and Risk of Dementia: Epidemiology, Mechanisms, and Effect of Anticoagulation. Front Neurosci. 2019;13:18. DOI:10.3389/fnins.2019.00018.

29. Santangeli P., Di Biase L., Bai R., et al. Atrial fibrillation and the risk of incident dementia: a metaanalysis. Heart Rhythm 2012;9(11):1761-8. DOI:10.1016/j.hrthm.2012.07.026.

30. Udompanich S., Lip G.Y., Apostolakis S., Lane D.A. Atrial fibrillation as a risk factor for cognitive impairment: a semi-systematic review. QJM. 2013;106(9):795-802. DOI:10.1093/qjmed/hct129.

31. Kalantarian S., Ruskin J.N. Atrial fibrillation and cognitive decline: phenomenon or epiphenomenon? Cardiology Clinics. 2016;34(2):279-85. DOI:10.1016/j.ccl.2015.12.011.

32. Graves K.G., May H.T., Jacobs V., et al. Atrial fibrillation incrementally increases dementia risk across all CHADS2 and CHA2DS2VASc strata in patients receiving long-term warfarin. American Heart Journal. 2017;188:93-8. DOI:10.1016/j.ahj.2017.02.026.

33. Ott A., Breteler M.M., de Bruyne M.C., et al. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke. 1997;28(2):316-21. DOI:10.1161/01.str.28.2.316.

34. Kilander L., Andren B., Nyman H., et al. Atrial fibrillation is an independent determinant of low cognitive function: a cross-sectional study in elderly men. Stroke. 1998;29(9):1816-20. DOI:10.1161/01.str.29.9.1816.

35. Thacker E.L., McKnight B., Psaty B.M., et al. Atrial fibrillation and cognitive decline: a longitudinal cohort study. Neurology. 2013;81(2):119-25. DOI:10.1212/WNL.0b013e31829a33d1.

36. Bunch T.J., Weiss J.P., Crandall B.G., et al. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer’s dementia. Heart Rhythm. 2010;7(4):433-7. DOI:10.1016/j.hrthm.2009.12.004.

37. de Bruijn R.F., Heeringa J., Wolters F.J., et al. Association between atrial fibrillation and dementia in the general population. JAMA Neurol. 2015;72(11):1288-94. DOI:10.1001/jamaneurol. 2015.2161.

38. Coma M., Gonzalez-Moneo M.J., Enjuanes C., et al. Effect of permanent atrial fibrillation on cognitive function in patients with chronic heart failure. The American Journal of Cardiology. 2016;117(2):233-9. DOI:10.1016/j.amjcard.2015.10.038.

39. Proietti M., Recchia A., Riva E., et al. Relationship between atrial fibrillation and cognitive decline in individuals aged 80 and older. European Journal of Internal Medicine. 2017;46:6-10. DOI:10.1016/j.ejim.2017.08.010.

40. Mielke M.M., Rosenberg P.B., Tschanz J., et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007;69(19):1850-8. DOI:10.1212/01.wnl. 0000279520.59792.fe.

41. Vermeer S.E., Den Heijer T., Koudstaal P.J., et al. Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke. 2003;34(2):392-6. DOI:10.1161/01.str.0000052631.98405.15.

42. Kalantarian S., Ay H., Gollub R.L., et al. Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis. Annals of Internal Medicine. 2014;161(9):650- 8. DOI:10.7326/M14-0538.

43. Gaita F., Corsinovi L., Anselmino M., et al. Prevalence of silent cerebral ischemia in paroxysmal and persistent atrial fibrillation and correlation with cognitive function. Journal of the American College of Cardiology. 2013;62(21):1990-7. DOI:10.1016/j.jacc.2013.05.074.

44. Vermeer S.E., Prins N.D., den Heijer T., et al. Silent brain infarcts and the risk of dementia and cognitive decline. The New England Journal of Medicine. 2003;348(13):1215-22. DOI:10.1056/NEJMoa022066.

45. Choudhury N.A., DeBaun M.R., Rodeghier M., et al. Silent cerebral infarct definitions and full-scale IQ loss in children with sickle cell anemia. Neurology. 2018;90(3):e239-e246. DOI:10.1212/WNL.0000000000004832.

46. Chen L.Y., Lopez F.L., Gottesman R.F., et al. Atrial fibrillation and cognitive decline-the role of subclinical cerebral infarcts: the atherosclerosis risk in communities study. Stroke. 2014;45(9):2568- 74. DOI:10.1161/STROKEAHA.114.005243.

47. Goette A., Kalman J.M., Aguinaga L., et al. EHRA/ HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Europace. 2016;18(10):1455-90. DOI:10.1093/europace/euw161.

48. Goette A., Bukowska A., Lendeckel U. et al. Angiotensin II receptor blockade reduces tachycardiainduced atrial adhesion molecule expression. Circulation. 2008;117(6):732-42. DOI:10.1161/CIRCULATIONAHA.107.730101.

49. Goette A., Ittenson A., Hoffmanns P., et al. Increased expression of P-selectin in patients with chronic atrial fibrillation. Pacing and Clinical Electrophysiology. 2000;23(11, pt2):1872-5. DOI:10.1111/j.1540-8159.2000.tb07041.x

50. Poggesi A., Inzitari D., Pantoni L. Atrial fibrillation and cognition: epidemiological data and possible mechanisms. Stroke/ 2015;46(11):3316-21. DOI:0.1161/STROKEAHA.115.008225.

51. Knecht S., Oelschlager C., Duning T., et al. Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy. Eur Heart J. 2008;29(17):2125-32. DOI:10.1093/eurheartj/ehn341.

52. Petersen P., Kastrup J., Videbæk R., Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. Journal of Cerebral Blood Flow & Metabolism. 1989;9(3):422-5. DOI:10.1038/jcbfm.1989.62.

53. Gardarsdottir M., Sigurdsson S., Aspelund T., et al. Atrial fibrillation is associated with decreased total cerebral blood flow and brain perfusion. Europace. 2018;20(8):1252-8. DOI:10.1093/europace/ eux220.

54. Wardlaw J.M., Smith C., Dichgans M. Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging. Lancet. Neurology. 2013;12(5):483-97. DOI:10.1016/S1474-4422(13)70060-7.

55. Poggesi A., PasiM., Pescini F., et al. Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: a review. Journal of Cerebral Blood Flow and Metabolism. 2016;36(1):72-94. DOI:10.1038/jcbfm.2015.116.

56. De la Torre J.C. Alzheimer disease as a vascular disorder: Nosological evidence. Stroke. 2002;33:1152-62. DOI:10.1161/01.STR.0000014421.15948.67.

57. Dietzel J., Haeusler K.G., Endres M. Does atrial fibrillation cause cognitive decline and dementia? Europace. 2018;20:408-19. DOI:10.1093/europace/eux031.

58. Rollo J., Knight S., May H.T., et al. Incidence of dementia in relation to genetic variants at PITX2, ZFHX3, and ApoE ε4 in atrial fibrillation patients. PACE. 2015;38:171-7. DOI:10.1111/pace.12537.

59. Mitchell A.R. Is rate more important than rhythm in treating atrial fibrillation? No. BMJ. 2009;339:b3174. DOI:10.1136/bmj.b3174.

60. Ganesan A.N., Shipp N.J., Brooks A.G., et al. Long-term outcomes of catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Journal of the American Heart Association. 2013;2(2):e004549. DOI:10.1161/JAHA.112.004549.

61. Gaita F., Scaglione M., Battaglia A., et al. Very long-term outcome following transcatheter ablation of atrial fibrillation. Are results maintained after 10 years of follow up? Europace. 2018;20(3):443- 50. DOI:10.1093/europace/eux008.

62. Kawaji T., Shizuta S., Morimoto T., et al. Very long-term clinical outcomes after radiofrequency catheter ablation for atrial fibrillation: a large single-center experience. International Journal of Cardiology. 2017;249:204-13. DOI:10.1016/j.ijcard.2017.09.02.

63. Haeusler K.G., Kirchhof P., Endres M. Left atrial catheter ablation and ischemic stroke. Stroke. 2012;43(1):265-70. DOI:10.1161/STROKEAHA.111.627067.

64. Herm J., Fiebach J.B., Koch L., et al. Neuropsychological effects of MRI-detected brain lesions after left atrial catheter ablation for atrial fibrillation: long-term results of the MACPAF study. Circulation: Arrhythmia and Electrophysiology. 2013;6(5):843-50. DOI:10.1161/CIRCEP.113.000174.

65. Bunch T.J., Crandall B.G., Weiss J.P., et al. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J Cardiovasc Electrophysiol. 2011;22(8):839-45. DOI:10.1111/j.1540-8167.2011.02035.x.

66. Salas M., In’t Veld B.A., van der Linden P.D., et al. Impaired cognitive function and compliance with antihypertensive drugs in elderly: the Rotterdam Study. Clin Pharmacol Ther. 2001;70:561-6. DOI:10.1067/mcp.2001.119812.

67. El-Saifi N., Moyle W., Jones C., Tuffaha H. Medication Adherence in Older Patients With Dementia: A Systematic Literature Review. J Pharm Pract. 2018;31:322-34. DOI:10.1177/0897190017710524.

68. Flaker G.C., Pogue J., Yusuf S., et al. Cognitive Function and Anticoagulation Control in Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes. 2010;3:277-83. DOI:10.1161/CIRCOUTCOMES.109.884171.

69. Raparelli V., Proietti M., Cangemi R., et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Thromb Haemost. 2017;117:209-18. DOI:10.1160/TH16-10-0757.

70. Xian Y., O’Brien E.C., Liang L., et al. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA. 2017;317:1057. DOI:10.1001/jama.2017.1371.

71. Coleman C.I., Roberts M.S., Sobieraj D.M., et al. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res Opin. 2012;28:669-80. DOI:10.1185/03007995.2012.677419.

72. Rossi A.P., Facchinetti R., Ferrari E., et al. Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2018;46:139-44. DOI:10.1007/s11239-018-1679-1.

73. Andrade J.G., Krahn A.D., Skanes A.C., et al. Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. Can J Cardiol. 2016;32:747-53. DOI:10.1016/j.cjca.2015.09.023.

74. Laliberté F., Nelson W.W., Lefebvre P., et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther. 2012;29:675-90. DOI:10.1007/s12325-012-0040-x.

75. Mahtani K.R., Heneghan C.J., Glasziou P.P., Perera R. Reminder packaging for improving adherence to self-administered long-term medications. Cochrane Database Syst Rev. 2011;(9):CD005025. DOI:10.1002/14651858.CD005025.pub3.

76. Bae J.P., Dobesh P.P., Klepser D.G., et al. Adherence and dosing frequency of common medications for cardiovascular patients. The American Journal of Managed Care. 2012;18(3):139-146.

77. Weeda E.R., Coleman C.I., McHorney C.A., et al. Impact of once- or twice-daily dosing frequency on adherence to chronic cardiovascular disease medications: a meta-regression analysis. International Journal of Cardiology. 2016;216:104-9. DOI:10.1016/j.ijcard.2016.04.082.

78. Yao X., Abraham N.S., Alexander G.C., et al. Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation. Journal of the American Heart Association. 2016;5(2):e003074. DOI:10.1161/JAHA.115.003074.

79. Beyer-Westendorf J., Ehlken B., Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace. 2016;18(8):1150-7. DOI:10.1093/europace/euv421.

80. McHorney C.A., Crivera C., Laliberte F., et al. Adherence to non-vitamin-Kantagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure. Current Medical Research and Opinion. 2015;31(12):2167-73. DOI:10.1185/03007995.2015.1096242.

81. Crivera C., Nelson W.W., Bookhart B., et al. Pharmacy quality alliance measure: adherence to nonwarfarin oral anticoagulant medications. Current Medical Research and Opinion. 2015;31(10):1889-95. DOI:10.1185/03007995.2015.1077213.

82. Camm AJ, Amarenco P, Haas S et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145- 53. doi:10.1093/eurheartj/ehv466.

83. Hecker J., Marten S., Keller L., et al. Effectiveness and safety of rivaroxaban therapy in daily-care patients with atrial fibrillation. Thromb Haemost. 2016;115:939-49. DOI:10.1160/TH15-10-0840.

84. Laliberté F., Cloutier M., Nelson W.W., et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Current Medical Research and Opinion. 2014;30(7):1317-25. DOI:10.1185/03007995.2014.907140.

85. Nelson W.W., Song X., Coleman C.I., et al. Medication persistence and discontinuation of rivaroxaban versus warfarin among patients with non-valvular atrial fibrillation. Current Medical Research Opinion. 2014;30(12):2461-9. DOI:10.1185/03007995.2014.933577.

86. Hankey G.J., Patel M.R., Stevens S.R. et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet. Neurology. 2012;11(4):315-22. DOI:10.1016/S1474-4422(12)70042-X.

87. Parfyonov V.A., Verbitskaya S.V. Secondary ischemic stroke prevention in patients with atrial fibrillation: results of the ROCKET AF study. Meditsinskiy Sovet. 2014;(5):6-11 (In Russ.)

88. Kelly-Hayes M., Beiser A., Kase C.S., et al. The influence of gender and age on disability following ischemic stroke: the Framingham study. Journal Stroke Cerebrovascular Diseases. 2003;12(3):119- 26. DOI:10.1016/S1052-3057(03)00042-9.

89. Graff J., von Hentig N., Misselwitz F., et al. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. Journal of Clinical Pharmacology. 2007;47(11):1398-407. DOI:10.1177/0091270007302952.

90. Stroke & Cognition. Navagate Esus. [cited by Feb 10, 2019]. Available from:


For citations:

Ostroumova O.D., Kochetkov A.I., Korchagina S.P., Ostroumova T.M., Chernyaeva M.S., Kirichenko A.A. Anticoagulant Therapy as a Tool for the Prevention of Cognitive Impairment Associated with Atrial Fibrillation. Rational Pharmacotherapy in Cardiology. 2019;15(5):713-724. (In Russ.)

Views: 651

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)